OOIR: Observatory of International Research

Papers

(The median citation count of Journal of Pharmacy and Pharmaceutical Sciences is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
The need to redefine diabetic cardiomyopathy as a unique clinical entity that requires pharmacotherapy	85
Evaluating the Effects of Agomelatine on Polysomnography Parameters in Patients with Obstructive Sleep Apnea.	51
Corrigendum: Applications of exhaled breath condensate analysis for drug monitoring and bioequivalence study of inhaled drugs	44
Comparing broad and narrow phenotype algorithms: differences in performance characteristics and immortal time incurred	40
Therapeutic update on oral potassium exchange resin use in chronic kidney disease patients: a systematic review of randomized controlled clinical trials	35
Effect of Oregon grape root extracts on P-glycoprotein mediated transport in in vitro cell lines	29
Drug-disease interaction: Clinical consequences of inflammation on drugs action and disposition	27
Monkeypox: Virology, Pathophysiology, Clinical Characteristics, Epidemiology, Vaccines, Diagnosis, and Treatments	24
Network pharmacology and molecular docking reveal the immunomodulatory mechanism of rhubarb peony decoction for the treatment of ulcerative colitis and irritable bowel syndrome	23
Applications of Exhaled Breath Condensate Analysis for Drug Monitoring and Bioequivalence Study of Inhaled Drugs	21
Pharmacological increases in circulating ketones fail to alleviate the hypertrophic cardiomyopathy present in the Tafazzin knockdown mouse model of Barth syndrome	20
Forkhead box O1 transcription factor; a therapeutic target for diabetic cardiomyopathy	19
Dissolution-permeation approach for biopharmaceutical evaluation: a feasibility study using naproxen	19
Post-Marketing Safety of Vemurafenib: A Real-World Pharmacovigilance Study of the FDA Adverse Event Reporting System	17
Expanding the eligibility criteria for drugs in Canada’s time-limited health technology assessment and temporary drug access processes will further accelerate access to new medicines	17
From fasting to fat reshaping: exploring the molecular pathways of intermittent fasting-induced adipose tissue remodeling	16
Effects of dual therapy with betamethasone and tetracycline in a NC/Nga mouse model of atopic dermatitis	15
Refined pharmacovigilance assessment of immune checkpoint inhibitors-related bullous pemphigoid: a multi-methodological approach utilizing FAERS database	15
Real-world community hospital hyperglycemia management in noncritically ill, type 2 diabetic patients: a comparison between basal-bolus insulin and correctional insulin	14
Artificial intelligence directed computational protein design: lessons from COVID-19 for pandemic-ready vaccines and antibody therapeutics	13
Community pharmacists as antimicrobial resistance stewards: a narrative review on their contributions and challenges in low- and middle-income countries	12
Exploring the Role of Sodium-Glucose Cotransporter as a New Target for Cancer Therapy	12
Intrahepatic cholestasis of pregnancy associated with azathioprine: first quantitative disproportionality analysis using the FDA adverse event reporting system	11
Remdesivir-induced conduction abnormalities: A molecular model-based explanation	11
Development of a submicron emulsion-based delivery system to improve the anti-inflammatory activity of urolithin A	10

Gastrointestinal perforation associated with novel antineoplastic agents: A real-world study based on the FDA Adverse Event Reporting System	10
Data collection within patient support programs in Canada and implications for real-world evidence generation: the authors’ perspective	9
Metabolic flux in macrophages in obesity and type-2 diabetes	9
Old drugs, new weapons: current trends in repurposing therapies against antimicrobial resistance	9
Integration of real-world evidence from different data sources in health technology assessment	9
The role of acetylation in obesity-induced cardiac metabolic alterations	8
Evaluation of hematocrit-adjusted conversion strategies for mycophenolic acid and tacrolimus monitoring using volumetric absorptive microsampling in lung and renal transplant recipients	8
Formulating biopharmaceuticals using three-dimensional printing	8
A review to determine regulatorily and reimbursement successes of studies conducted using data from Canadian patient support programs based on the real-world evidence guidelines published by Canadian	7
Development of a dry powder formulation for pulmonary delivery of azithromycin-loaded nanoparticles	7
Persistence and switching patterns of migraine prophylactic medications in Canada: A retrospective claims analysis comparing adherence and evaluating the economic burden of illness	7
Clinical observation of dexmedetomidine nasal spray in the treatment of sleep disorders on the first night after undergoing maxillofacial surgery: a single-center double-blind randomized controlled st	6
Occurrence of intraocular hemorrhages under monotherapy or combination therapy of antiplatelets and anticoagulants using the Japanese Adverse Drug Event Report database	6
Adverse drug events associated with tiotropium: a real-world pharmacovigilance study of FDA adverse event reporting system database	6
Qualitative phytochemical profiling, antioxidant activity, and development of a water-in-oil cream containing combined oil and water infusions of frankincense resin (Boswellia spp.): a preliminary in	6
Compounding and stability studies of liquid oral formulations of beta-blockers (bisoprolol, betaxolol, and nadolol) for paediatric patients	6
A Survey of the Criteria Used for the Selection of Alternative Comparator Products by Participating Regulators and Organizations of the International Pharmaceutical Regulators Programme	5
Analysis of Prednisolone-Induced Osteoporosis Using the Japanese Adverse Drug Event Report Database	5
Chitosan non-particulate vaccine delivery systems	5
Quality by design in public healthcare: a rapid development framework for future pandemics	4
Zaleplon nanospanlastics loaded transdermal patches: formulation, optimization, ex-vivo permeation, and in-vivo studies	4
Weighing in on the role of brown adipose tissue for treatment of obesity	4
Corrigendum: Recent progress of polymeric microneedle-assisted long-acting transdermal drug delivery	4
The mechanism of Leonuri Herba in improving polycystic ovary syndrome was analyzed based on network pharmacology and molecular docking	4
A Review of Electronic Cigarettes and Liquid Nicotine Poisoning Exposure Cases in the United States	4
Targeted therapy and biomarker-guided applications of ecofriendly silver nanoparticles in precision oncology	3
Harnessing DNA polymerase beta defect enhances synthetic lethality and treatment response in gastric cancer cells: implication for immunotherapy	3
Targeting ketone body metabolism to treat fatty liver disease	3
Development of modular polymeric nanoparticles for drug delivery using amine reactive chemistry	3
Personalizing immunosuppressive therapy: predictors of drug switches in Malaysian kidney transplant recipients	3
Safety and efficacy of phosphodiesterase-5 (PDE-5) inhibitors in fetal growth restriction: a systematic literature review and meta-analysis	3
Rethinking asthma therapy, part 1: transdermal delivery of β2-agonists	3
Film dressings from Thai mango seed kernel extracts versus nanocrystalline silver dressings in antibacterial properties	3